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Abstract 9 
 Vaccination programs for childhood diseases, such as measles, mumps and rubella have greatly 10 
contributed to decreasing the incidence and impact of those diseases. Nonetheless, despite long 11 
vaccination programmes across the world, mumps has not yet been eradicated in those countries: 12 
indeed, large outbreaks continue. For example, in Scotland large outbreaks occurred in 2004, 2005 13 
and 2015, despite introducing the MMR (Measles- Mumps- Rubella) vaccine more than twenty years 14 
ago. There are indications that this vaccine-preventable disease is re-emerging in highly vaccinated 15 
populations. Here we investigate whether the resurgence of mumps is due to waning immunity, and 16 
further, could a booster dose be the solution to eradicate mumps or would it just extend the period of 17 
waning immunity? Using mathematical modelling we enhance a seasonally-structured disease model 18 
with four scenarios: no vaccination, vaccinated individuals protected for life, vaccinated individuals 19 
at risk of waning immunity, and introduction of measures to increase immunity (a third dose, or a 20 
better vaccine). The model is parameterised from observed clinical data in Scotland 2004-2015 and 21 
the literature. The results of the four scenarios are compared with observed clinical data 2004-2016. 22 
 While the force of infection is relatively sensitive to the duration of immunity and the number of 23 
boosters undertaken, we conclude that periodic large outbreaks of mumps will be sustained for all 24 
except the second scenario. This suggests that the current protocol of two vaccinations is optimal in 25 
the sense that while there are periodic large outbreaks, the severity of cases in vaccinated individuals 26 
is less than in unvaccinated individuals, and the size of the outbreaks does not decrease sufficiently 27 
with a third booster to make economic sense. This recommendation relies on continuous efforts to 28 
maintain high levels of vaccination uptake.   29 
1 Introduction 30 
To prevent, control and eradicate childhood diseases, vaccination programs have been adopted 31 
throughout the world. For example the trivalent measles-mumps-rubella vaccine (MMR) [1, 2, 3] has 32 
been highly successful for both measles and rubella reduction in many countries. Despite near 33 
eradication of both measles and rubella [4,5,6], elimination of mumps has not been achieved and 34 
could be considered to be re-emerging, despite initial early success in reducing mumps cases. In the 35 
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last decade, many countries such as Belgium [7], Korea [8], the Netherlands [9] and the US [10] have 36 
reported a dramatic increase in the incidence of mumps. In Scotland, 2004/2005 saw a sudden high 37 
resurgence in mumps with approximately 4500 cases, eight years after the second dose of MMR was 38 
included in the vaccination program (which was predicted to substantially reduce mumps outbreaks 39 
[11]).  One hypothesis is that the resurgence was related to declining vaccine coverage [12, 13], in 40 
particular, a widespread scare related to autism which led to some parents refusing to vaccinate their 41 
children. This can be easily debunked: the herd immunity threshold is estimated at 75-86% [14] and 42 
mumps vaccination levels have stayed above that level (e.g. in Scotland, ranging from 87% to 94% 43 
pre-2004). In addition Donaghy et al [14] argues that those infected during the 2004/2005 epidemics 44 
are characterised by low uptake of a single dose of MMR (catch-up campaign) and being of school 45 
age at time when the mumps virus had greatly reduced circulation in that group, delaying infection. 46 
The study undertaken by DeStefano et al [15] analysing the number of antigens in both children with 47 
and without autism, shows that there is no association between receiving vaccine and developing 48 
autism. 49 
A second hypothesis is to link vaccination status and age, e.g. proposing that outbreaks continue in 50 
the older population but die out in the increasingly vaccinated population. However, while age 51 
structure has shown to be informative in many models of traditionally childhood diseases [16, 17, 18, 52 
19], current studies suggest that age is not the key determinant in mumps. Snijders et al. [20] do not 53 
find any significant interaction between these two features. In addition, several studies of different 54 
outbreaks occurring at different times and locations in the US and Canada [21] indicate that there is 55 
no evidence that age is the main factor leading to mumps spread. For instance, the outbreaks 56 
occurring in New York (Sulivan, Brooklyn, Rockland county and Orange county), New Jersey and 57 
Canada show variable average of infected age groups (Sullivan: 12 years, Brooklyn: 14 years, 58 
Rockland county: 12 years, Orange county: 18 years, New Jersey: 19.5 years and Canada: 27.5). 59 
However, it was confirmed that all cited cases were related to religious events or camping in 60 
Sullivan, with the majority fully vaccinated. It was also reported that the series of outbreaks were due 61 
to one fully vaccinated child aged 11 years who had been infected during his travel to UK. Snidjer et 62 
al. [20] analysed a group of infected whose ages ranged in 3 to 13 years. The authors find out that no 63 
significant difference between the attack rate of the group aged 10-13 years and 3-5 years. 64 
Considering Scotland specifically, Donaghy et al. [14] argued that the shift of ages observed in the 65 
epidemic in Scotland suggests that the propagation of mumps is becoming more widespread and 66 
diverse as the targeted population becomes more dynamic and mobile.  67 
Having rejected the first two hypotheses, the arguments used lead to the third and more plausible 68 
hypothesis: MMR vaccine efficacy against mumps reduces over time [13]. In 2015 67% of those 69 
infected in Scotland were fully vaccinated individuals (1 and 2 doses confounded). Moreover, most 70 
primary cases occurred in adolescent and young adults, in contrast to the pre-vaccine era where 71 
outbreaks were among children of primary school age. Similar patterns can be found for Belgium in 72 
2012 [7] and in the US in 2006 [10]. Serological studies [8, 22] show that susceptibility level 73 
increases (immunity wanes) as time from vaccination increases; however, the antibody threshold 74 
defining the protective level is not well specified for mumps [23]. Even using two doses of the MMR 75 
vaccine, existing analyses [8, 24] stress that some of the population will remain at risk of disease 76 
unless additional control strategies are adopted.   77 
We investigate the hypothesis of waning immunity using mathematically-based computational 78 
modelling. The basic model is a seasonal compartmental SEIR model [25, 26, 27], to which 79 
vaccination and immunity is added. We first show that the model produces comparable results to 80 
observed mumps data in Scotland [28], matching endemic levels of mumps with occasional larger 81 
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epidemics, as in 2005 and 2015. Having established the accuracy of the model with historical data, 82 
we use it predictively to better understand the relationship between immunity and transmission, to 83 
illuminate long-term patterns of resurgent outbreaks, and to determine whether these can be 84 
controlled by extending immunity duration (e.g. by using another booster). While modelling has been 85 
previously used to investigate mumps and vaccination [7, 27, 29], the novelty of our approach lies in 86 
consideration of waning immunity and associated optimal control strategies. Our model shows 87 
clearly that waning immunity is a driver for  a long period of oscillating outbreaks. Moreover, by 88 
working with epidemiologists to use mathematics to understand the observed clinical data, we 89 
illustrate the power of mathematics to inform public health policy through multi-disciplinary 90 
collaboration. 91 
2 Mumps epidemiology in Scotland  92 
During the period 1988-2015, Health Protection Scotland (HPS), the national surveillance centre for 93 
Scotland, reported 10943 mumps cases. 10486 of these cases were between 2004 and 2015. 94 
Vaccination was introduced in 1988, with a second dose introduced in 1996. Fig. 1 shows the 95 
epidemic curve of mumps, and the vaccination uptake curves for both vaccines (MMR1 and MMR2). 96 
Observe the initial success of the vaccine (1988-2003) contrasted with a long potential cycle from 97 
2004-2015, possible with sub-cycles (2005-2009, 2009-2012, 2012-2015). The 2004/2005 outbreak 98 
was related only partly to the decrease in vaccination coverage shown in Fig. 1 [14]. The majority of 99 
cases (94%) were born before 1990 (aged 15+ years), with only a few of them receiving only one 100 
dose of MMR (around 1%) or none at all. Similarly for the outbreaks in 2009 and 2012. In 2015 the 101 
highest incidence of mumps (63%) was related to the group born 1991-2000 (aged 15-24 years). 102 
Cameron and Smith-Palmer [24] argue that the 2015 outbreak was the first where the majority of 103 
cases were fully vaccinated. Transmission is a complex feature to model as it can be influenced by 104 
many factors (vaccination history, current immunity status, age, opportunity for social mixing, 105 
geography, and so on). Moreover, some of these factors are confounded (e.g. age and vaccination 106 
history). We propose in this model that vaccination history is used as a proxy for these combined 107 
effects. Therefore, the main question arising is: why are vaccinated individuals being infected? Here 108 
we focus on the long curve (2005-2015) relating to the long inter-epidemic period.  We explore these 109 
features within the model presented in Section 3, using the Bio-PEPA plugin tool [30] and 110 
deterministic simulation to provide time series prediction of the number of infected individuals. The 111 
model is parameterised and validated on data up to 2015, and then to further validate its predictive 112 
performance it is shown to match 2016 data provided by HPS. The advantages for using the Bio-113 
PEPA formalism (a mathematically-defined computational modelling approach called process 114 
algebra) have been fully argued in many works [30, 31, 32]. Here, the advantages are: formal 115 
structuring of interactions between components, a compositional approach to building the 116 
epidemiological model, and a range of analysis techniques to support the modeller in understanding 117 
the system. The underlying semantics of Bio-PEPA is a continuous time Markov chain. 118 
3 Methods 119 
3.1 Model structure, epidemiological assumptions and parameter estimates 120 
We consider a compartmental structure for a model of mumps formulated as an extended SEIR [11] 121 
model including seasonality and waning immunity: natively susceptible (S1), vaccinated individuals 122 
with MMR1 only (V1), vaccinated individuals with both MMR1 and MMR2 (V2), modified 123 
susceptible who are vaccinated individuals who have become susceptible (S2), exposed individuals 124 
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(E), infected individuals (I) and recovered individuals who are regarded as immune for life (R) [11, 125 
33]. Fig. 2 shows how these compartments interact.  126 
Our goal is to provide as simple a model as is necessary to demonstrate the impact of waning 127 
immunity, therefore we have ignored features which others have chosen to include. For example, the 128 
models of Glass and Grenfell [34] and Barbarossa and Röst [35] include immunity levels and 129 
immune-boosting through vaccination and interactions with infected. Since we have no data on 130 
antibody levels as individuals interact we choose not to include this, choosing the simpler scenario 131 
which can be parameterised through observed data. Neither do we include age-structure, as mumps 132 
has ceased to be a mainly childhood disease. As shown in several works [14, 36, 37, 38], the range of 133 
those infected with mumps has become more diverse due to a more mobile susceptible population. 134 
Therefore, rather than stratifying the population by age, we assume a more homogenously-mixed 135 
population, with routine vaccination, and transmission based on seasonality and immunity status.  136 
This model is general and could be parameterised for any seasonal disease with up to two 137 
vaccinations. We use data from Health Protection Scotland (HPS) from 2004-2016 [28] and some 138 
parameters from the literature [11, 39]. These are detailed in Table 1, with some explanatory text. 139 
 Demographic estimation 140 
Birth and death rate estimated from Scottish demographic data [28].  141 
 Immigration rate estimation 142 
As the net migration to Scotland is insignificant (typically 15,000 per year), the model has been 143 
simplified by having neither mass emigration nor immigration of susceptible individuals. A small 144 
constant rate of immigration of infected individuals is required to prevent the disease dying out 145 
entirely. This is justified by the knowledge that there is immigration, and there are many populations 146 
in the world where mumps is more prevalent and the global population is more mobile, transmitting 147 
disease between countries. A small rate of immigration of infectious individuals is estimated as in 148 
Finkenstadt et al [40] and Benkirane et al [31].  149 
 Vaccination rates estimation (μ2, μ3) 150 
According to vaccination data [41], our basic assumption is an average of 94% MMR1 vaccination 151 
coverage (1988-2016) for children aged 0 to 2 years and 90% MMR2 vaccination coverage (1996-152 
2016) for children aged 3 to 5 years. According to past vaccination history [42, 43], we estimate the 153 
susceptible portion of the remaining unvaccinated population at 20%. Within that proportion of 154 
susceptible we consider 11% of those to be aged ten years or over according to current demographics. 155 
It would be more realistic to consider a varying vaccination rate each year; however, we did not want 156 
this to confound the patterns obtained through simply waning immunity. We do investigate scenarios 157 
in which these average vaccination rates are varied across the simulation period, to show how this 158 
affects the pattern of outbreaks. 159 
 Waning immunity estimation (, ) 160 
Our basic assumption is individuals vaccinated with MMR1 and MMR2 (resp. only MMR1) are 161 
temporarily protected and that immunity wanes towards susceptibility at constant rate  (resp. ). 162 
Lebaron et al [23] report low antibody levels 4-9 years after MMR1 only, and 7-12 years after 163 
MMR2 administration. We also investigate scenarios in which these rates are varied. 164 
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 Transmission rate estimation (1, 2, 3) 165 
In our model, the transmission rate depends on two features: seasonality (High, Low) and type of 166 
susceptible (native susceptible, modified susceptible) giving four rates: 1 (High season and native 167 
susceptible), 2 (high season and modified susceptible, 3 (low season and native susceptible), 4 168 
(low season and modified susceptible). For seasonality, data report higher number of cases October 169 
to May, and fewer between June and September [28]. As most cases occurs in 17-24 year-olds this 170 
seasonality is further supported through an assumption that many of that group are likely to be in 171 
full-time education, and mixing more in semester-time than in the holiday. As the total number of 172 
infected at low season is small we assume 3 = 4. In addition, we assume 2 > 1 (transmission in 173 
modified susceptible is higher than in native susceptible). This follows from the model of Scherer 174 
and McLean [45], and is supported by the report of Cameron [44] that within 205 confirmed cases 175 
related to two health boards, 137 (67%) individuals were fully vaccinated. As transmission rate is 176 
based on the basic reproduction number R0 (see Table 1), a range of proposed values were collected 177 
from literature [11, 13, 27], where R0 is ranged [4-11]. See section 5 for sensitivity analysis of the 178 
particular choices of these rates. 179 
 Incubation rate  and recovery rate  180 
Established empirical studies [11, 27] estimate the incubation period between 12-25 days and the 181 
infectious period between 7-9 days [27]. For modelling convenience, we assume the same period of 182 
infection and incubation [43] for both natively susceptible and modified susceptible. 183 
 Initial conditions 184 
The initial mix of susceptible, vaccinated, exposed, infected and recovered is calculated for 1996 185 
according to the above assumptions about population based on vaccination beginning in 1988. See 186 
appendix 1 (model component).  187 
The description of the model and parameters above can be summarised by seven ordinary differential 188 
equations:  189 
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Where:                       
                                        
                            
    197 
This model is coded in Bio-PEPA (see Appendix 1). Analysis of the model is performed through 198 
deterministic simulation. Stochastic simulation was used to guide model development but does not 199 
provide additional information when identifying long term trends. 200 
3.2 Model scenarios  201 
To capture the impact of vaccination efficacy and the effect of waning immunity on the population of 202 
Scotland for future projection of epidemics, the history of mumps epidemics (from pre-vaccine to 203 
post-vaccine era) are reproduced where four strategies are considered:  204 
 Scenario one. No vaccination. This is equivalent to the pre-vaccine era and useful for model 205 
validation where the whole population is considered susceptible. 206 
 Scenario two. Immunity does not wane:  and  are zero. This case reflects the introduction of a 207 
vaccination protocol to case one, where immunity is assumed to be for life. This is consistent 208 
with the period immediately following the introduction of vaccination. 209 
 Scenario three. Immunity wanes in vaccinated individuals according to the assumptions above. 210 
This scenario reflects modern reality, where mumps is resurgent. Our model is extended to two 211 
separate but correlated models: the first model expresses unvaccinated individuals and the 212 
second model expresses vaccinated individuals for whom immunity wanes. Scenario three is an 213 
extension to case two by introducing the terminology of waning immunity.  214 
 Scenario four. An additional medical intervention increases immunity duration. We explore 215 
immunity duration across a range (10 to 80 years). This case is a particular variation of case 216 
three, where the immunity duration is specified in the defined range. This scenario is to 217 
predictively investigate possible future interventions. 218 
4 Results 219 
According to observed mumps data in Scotland in Fig. 1, and in conjunction with observed mumps 220 
data in England and Wales in Fig. 9 (a and b) (see Appendix 3), three different periods of an 221 
epidemiological shift in incidence are observed: pre-vaccine, successful post-vaccine and waning 222 
immunity period.  Fig. 3 depicts time series results for infected cases under scenarios 1-3. Overall, it 223 
is clear that mumps occurs every year, regardless of vaccination or waning immunity; however, those 224 
factors control the amplitude of the epidemic and the frequency of the highest peaks driving a long 225 
term damping oscillation of large outbreaks. After 100 years the difference between the high and low 226 
of the cycle is around 25 cases. 227 
Scenario One (no vaccination = pre-vaccine era) 228 
We begin by checking model performance without vaccine. Fig. 3 (a) shows an inter-epidemic period 229 
of three years within an oscillatory pattern of mumps cases. This matches parameter values of 230 
incubation period of 13 days, infectious period of seven days and a mean age of infection of five 231 
years (all within the ranges of Table 1). This is supported by the incidence of mumps in England and 232 
Wales [27] and observations in the literature reporting cycles of 2-5 years [29, 46].  233 
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 234 
We point out that predicted cycles do not damp out during 100 years of simulations. By varying 235 
seasonality parameter of the model, including removing seasonality altogether, we observed that after 236 
a long period the model reaches an endemic state. To further reinforce the suitability of the model we 237 
considered R0 ranging from [7 - 14]. Fig. 4 (see Appendix 3) shows that increasing R0 leads to 238 
decreasing the inter-epidemic period from 5 years to 3 years. 239 
Scenario Two (up to two vaccinations and immunity is permanent = immediate post-vaccine era) 240 
Turning to the successful post-vaccine era (and assuming life-long immunity), Fig. 3 (b) and (d) 241 
show a massive decrease of mumps infections consistent with observed data 1988-2003, where 242 
waning immunity was not yet an important factor and the number of cases overall dramatically 243 
decreased due to the decreased pool of susceptibles, in turn due to vaccination. Again, this helps to 244 
confirm that the model successfully models historical data. 245 
Scenario Three (up to two vaccinations and immunity wanes) 246 
Fig. 3 (c) (resp. Fig.3 (d)) shows model prediction against observations from Scotland in the post-247 
vaccine era (2004-2016, resp. 1996-2016). Fig. 3 (c) shows pattern of mumps outbreaks from 2004 to 248 
2016 as waning immunity begins to be more relevant. The simulated data (black solid line) displayed 249 
in Fig. 3 (c) depicts patterns of mumps dynamics qualitatively similar to observed data (gray solid 250 
line). Mumps is notoriously under-reported [47] as, especially for those in whom immunity has 251 
waned, the disease is often milder (and infected do not seek medical attention). Our model has no 252 
notion of “level” of infection, therefore sub-clinical, mild, and serious infections are all counted and 253 
contribute to disease transmission. Observed data is scaled by two to compensate for under-reporting 254 
of mumps. This is a conservative estimate, based on higher uptake of vaccine in Scotland than in 255 
Germany [47].  This is discussed further in section 6.  256 
Fig. 3 (d) shows that 2005/2015 years were the dominant period reflecting the highest peaks of 257 
mumps infection. Some notable gaps are observed (2009, 2010 and 2012); the observed mumps 258 
dynamics are inherently stochastic and noisy. Fig. 3 (c,d) depicts that the simulated data for the year 259 
2016 follows the same patterns as observed data, where the number of infected start to decrease. 260 
Qualitatively, the simulation results show that even if vaccination is applied, mumps is occurring 261 
each year, where the seasonal patterns of our model depict that the infection increases rapidly over 262 
the last few months of the year and the high peak is reached early at the start of the year. This is 263 
broadly in agreement with observed data.  264 
Vaccination coverage dips in this period, but this is not the main factor leading to the resurgence and 265 
sustainability of mumps, nor is seasonality on its own (as above). We investigate the variability of 266 
vaccination coverage by ranging its value from [75 - 95], where 75% is the minimum value related to 267 
the threshold level and 95% is the maximum value of applied vaccine coverage in Scotland. Fig. 5 268 
(see Appendix 3) shows that increasing vaccine coverage leads to a decrease in the peak of infected
1
 269 
(from 1694 to 1413). This is 16%, and still produces a large number of cases. Therefore, increasing 270 
the vaccination coverage does not prevent disease occurrence. In addition, we note that all 271 
experiments (vaccination coverage ranging from [80 – 95]) settle into a ten year pattern of gently 272 
                                                 
1
 Average number of infected corresponds to the average of the highest peaks during 100 years of simulations. 
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damping oscillations (100 years of simulation), where the large oscillations are up to 2045, and 273 
thereafter the outbreaks become more and more regular in height. 274 
To further investigate the impact of waning immunity Fig. 6 depicts separately those infected-275 
unvaccinated and those infected-vaccinated against natively susceptible and modified susceptible 276 
over 100 years of temporal prediction. As expected, due to increasing levels of vaccinated individuals 277 
in the population, the number of natively susceptibles and infected-unvaccinated decreases over time, 278 
reaching a steady state of infection of around 200 individuals. Conversely, waning immunity leads to 279 
an increase in the number of modified susceptible and infected-vaccinated, settling into a ten year 280 
pattern with peaks of between 800 and 1200. Therefore, waning immunity and its effects are the 281 
dominant portion of any epidemic.  282 
Scenario Four (additional booster - up to three vaccinations and immunity wanes) 283 
Further, we consider scenario 4: the impact of increasing the period of immunity by applying an 284 
additional dose of MMR [44]. This could be similarly done by increasing immunity by increasing the 285 
efficacy of the vaccination [43]. We investigate increasing immunity duration in steps from 10 to 80 286 
years (broadly, life expectancy). Fig. 7 compares these scenarios and shows that the average of the 287 
number of infected individuals at the peak of each outbreak decreases with increasing duration of 288 
immunity, as expected.  289 
5 Sensitivity analysis 290 
The results above depend on precise parameter values, therefore we used sensitivity analysis to show 291 
that the qualitative results of periodic large outbreaks hold across the range. We identify significant 292 
parameters reproducing first the observed data, and second leading to the low level endemic state.  293 
Table 2 shows the impact on epidemic amplitude and the periodicity of damping cycles of a series of 294 
experiments during 100 years of simulation varying model parameter values for: transmission rates 295 
(β1, β2, β3), infectious period (), incubation period (),  immunity duration (, ) and vaccination 296 
rate. The values of the remaining parameters (birth rate, death rate and immigration rate) are fixed. 297 
For all analysis we used ANOVA as implemented in Minitab [48]. The full details of the analysis are 298 
in Appendix 2: as expected, only varying transmission rates and immunity duration impact on results. 299 
Increasing R0 leads to a decrease in period between large outbreaks and therefore an increase in the 300 
number of oscillations (see Fig. 8, Appendix 3). Smaller immunity durations increase the pool of 301 
susceptibles faster and therefore lead to larger and earlier epidemics. 302 
6 Discussion  303 
Our analysis shows that mumps epidemics will continue, with larger outbreaks of ~1200 every 10 304 
years as shown in Fig 6, eventually settling into an endemic state. This is despite high vaccination 305 
coverage against mumps (87- 95%) since 1988 in Scotland [28] (well above the estimated herd 306 
immunity threshold of 75-86% [14]).  307 
In this paper, we have presented the results of mathematical modelling using Bio-PEPA, identifying 308 
the impact of vaccination and waning immunity in the mumps component of the MMR vaccine. Even 309 
though vaccination has been ongoing since 1988, thus largely preventing mumps in children, our 310 
results show that waning immunity is the main factor in a repeated pattern of outbreaks. Simulations 311 
and analysis undertaken showed that waning immunity over 10 years leads to the highest number of 312 
infected and to the longest inter-epidemic period for larger outbreaks. 313 
Prov s
i al
  Running Title 
 
9 
The first part of this study was to build a seasonal model which reproduces the patterns of the 314 
observed data in three scenarios: no vaccination, initial post-vaccine period with immunity for life, 315 
and with waning of vaccine-induced immunity as suggested by several sources [7, 8, 9, 10]. Those 316 
show that mumps is present in previously vaccinated individuals with the majority of those affected 317 
being university students. While based on Scottish data this is not a peculiarly Scottish phenomenon: 318 
for example, in the US [1], Korea [8] and the Netherlands [9] adolescent individuals were notified as 319 
infected despite high vaccine coverage. In these countries, it was observed that the majority of cases 320 
were in young adult (18 to 25 years) who have been fully vaccinated. In the US, where the first dose 321 
of MMR was introduced in 1977 and the second dose in 1990, the outbreak occurring in 2006 322 
reached 6584 cases,63% of whom received two doses of vaccine. For this country it was reported that 323 
in 1982 the incidence rate was reduced to 97% and the three year cycles observed in the pre-vaccine 324 
era disappeared. Moreover, in 2005, one year before the resurgence of the outbreak occurred in 2006, 325 
the incidence rate was damped to up to 99% where the vaccine coverage reached 91.5%. In the 326 
Netherlands, the large epidemic which occurred in 2004 led to the reintroduction of mumps as a 327 
notifiable disease. This followed its removal from the notifiable disease register in 1999 as a 328 
consequence of low outbreaks and vaccination coverage of at least one dose of MMR of at least 93% 329 
since the introduction of routine vaccine in 1987 . In Korea, the epidemic of 2013-2014 showed that 330 
99% of infected individuals aged from 13 to 18 years have been fully vaccinated. It is worth noting 331 
that Korea is not that different from other countries as in the pre-vaccine era the epidemic cycles 332 
were identified at 4 to 5 years and the mean age of infection at 4 to 6 years which shifted to teenagers 333 
in the recent outbreaks (2007 and 2013) in time when vaccination coverage rose to 90%.   334 
Waning immunity is expressed in our model by including an additional compartment of modified 335 
susceptible, which is increased by vaccinated individuals (MMR1 and MMR2) losing their immunity. 336 
We find that assuming 5 years of MMR1 vaccine-induced immunity (resp. 10 years of MMR2 337 
vaccine-induced immunity) generates simulation results consistent with more recent mumps post-338 
vaccine data from Scotland (2004-2015). In addition, as our model suggests a ten-year-long gradually 339 
damping oscillation, the following trajectory of mumps disease would show a decrease in 2016 and 340 
so on, building back up from 2020 to another high peak in the year 2025. The most recent data 341 
provided by HPS has confirmed this prediction, where the year 2016 depicts 215 cases compared to 342 
2015 which defines 836 cases. Although our estimates of the amplitude of mumps epidemics are 343 
higher than observed data, we conjecture that this can be explained by a low level of reporting. 344 
Anecdotally, cases of mumps in vaccinated individuals have much milder symptoms and therefore 345 
may be undetected [43, 47, 49, 50]..  346 
By considering different values of immunity duration (scenario 4) we can estimate the time needed to 347 
reverse the epidemic trend and eliminate mumps. This models the situation that, for example, a new, 348 
more effective, vaccine is introduced, or a third vaccine dose is introduced into the national 349 
programme. This is shown in Fig 7. Even extending immunity to 80 years, a reasonable lifespan, 350 
mumps outbreaks still occur. Only by further increasing immunity duration to 150 years eliminates 351 
mumps outbreaks, assuming no perturbations occur such as a new vaccine or new strain of mumps. 352 
It is worth noting that the basic reproductive number R0 for the pre-vaccine era is estimated at 10.5 353 
which falls in the range [7-14] as cited in literature [11, 39] and for the post-vaccine era R0 is 354 
estimated at 6 where in the literature it is quoted at [4-7] [29, 51]. Recall that R0 indicates the number 355 
of secondary infections, clearly showing that the number of doses of vaccination and immunity 356 
duration has a great impact on decreasing infectious contacts. 357 
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Cumulatively, our findings suggest that the more "unprotected" individuals (who were either never 358 
vaccinated or lost their immunity), the shorter the period between two high peaks of epidemic 359 
outbreak (note the number of cycles in Table 2 for varying values of R0). In addition, in both cases 360 
related to scenarios 1 and 3 (No vaccination and waning immunity), an earlier high peak of mumps is 361 
expected. This occurs because the pool of susceptibles is increasing faster as those vaccinated lose 362 
their immunity and move to the susceptible state (scenario 3), or the pool of susceptibles is 363 
decreasing faster when no vaccination is applied and R0 is higher (scenario 1). Clearly, controlling 364 
the number of susceptible individuals has a great impact on controlling disease. As argued by Gay 365 
[52]: to achieve elimination of an epidemic, low levels of susceptible individuals should be 366 
maintained, leading the basic reproductive number (R0) to be less than 1. We do this here by 367 
adjusting immunity duration. 368 
These conclusions illustrate an enhanced understanding of mumps disease in response to mass 369 
immunization gained through mathematical modelling. Further, our multi-disciplinary team could 370 
explore the potential impact of further vaccination on cyclic outbreaks. Our conclusion for public 371 
health services is that they should urge vaccine uptake in those eligible since a high degree of 372 
protection is offered by the vaccine overall for those under 18. Considering the possible economic 373 
cost/benefit of a third vaccine dose, it seems that while there would be an increased period of 374 
immunity, the cyclic outbreaks would continue at about 2/3 the current level, therefore this would not 375 
offer significant advantages over the present situation. The Joint Committee on Vaccination and 376 
Immunization
2
 do not consider these large outbreaks of particular concern, since there has been no 377 
formal discussion to introduce a 3
rd
 vaccine dose into the national programme. 378 
 We suggest further study with this model could include vaccination programmes targeted to those 379 
subject to waning immunity or at higher risk due to social mixing in a diverse population (as in 380 
higher education). Such a model might also include economic factors to allow the effect of targeted 381 
programmes to be more precisely evaluated. Another interesting facet would be to bring more 382 
attention to the level of immunity by analysing the vaccine/virus content and detect eventual 383 
discrepancy between vaccine strain and mumps outbreak. This might also be linked with a data 384 
science approach to analysing serology of confirmed cases. There are further opportunities to use 385 
data science to analyse other features, such as geographic distribution. These developments would 386 
allow an enhanced version of Fig. 6 showing waves of outbreaks related to waning immunity, 387 
evolution of strains of mumps, and locality. 388 
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10 Appendix 1: Bio-PEPA Model 509 
A Bio-PEPA model, illustrated below, is defined by three main components: species, functions of 510 
species dynamics and rates at which those species evolve. Modelling mumps in Bio-PEPA requires 511 
describing fully those features accordingly to the model in Fig. 2 and its description above. 512 
Rates. All rates fully described in Table 1 are reported in Bio-PEPA code, from line 1to 12. In 513 
addition, Bio-PEPA defines the parameter “location” (from line 13 and line 18). As in our model, the 514 
population is considered homogeneous, therefore all individuals belong to the same space. 515 
Seasonality is expressed by using the Heaviside function (H). As noted by Marco et al. [53]: ” 516 
Heaviside function (H) is used to switch customised behaviours on or off in the kinetic laws, this 517 
gives a binary valued function from time”. The lines from 19 to 22 code two seasons. The system 518 
moves instantaneously from the high epidemic season defined from October to May to the low 519 
epidemic season defined from June to September. 520 
Species and Functional rates (KineticLawOf). According to the compartments shown in Fig. 2, seven 521 
species are defined: S1, S2, V1, V2, E, I, R. Species carry out actions (kinetic laws) leading to 522 
increase/decrease their level (from line 24 to 40). Actions occur at a rate determined by the kinetic 523 
law. Most of these kinetic laws are simple mass action terms defined by the parameters described in 524 
the Table 1. Since species interact, the dynamics of each species may affect the level of other species. 525 
The scale of this dynamic is bounded by the functional rate specified for each species. For example 526 
the action described in line 34, related to incubation and used both by species “E” and “I”, leads to a 527 
decrease in the Exposed species (line 43) expressed by the operator “<<”, while it leads Infected 528 
species to increase using the operator “>>”. Bio-PEPA species can carry out different activities at 529 
each time step, by using the operator ‘+’. 530 
The last line of the model (line 48) defines the interaction between species, and their initial sizes. 531 
Parameters 532 
1 D_R = 0.000037; 533 
2 Beta1 =0.80; 534 
3 Beta2 =1.03; 535 
4 Beta = 0.45; 536 
5 Mu2= 0.0000028; 537 
6 Mu3= 0.000025; 538 
7 Mu1 = 0.0000021;  539 
8 Alpha = 0.05; 540 
9 Gama  = 0.167; 541 
10 imrate1 =0.07; 542 
11 Tau= 0.00034; 543 
12 Delta=Tau/2; 544 
13 sizeOutside = 110000; 545 
14 sizeLocal = 5300000; 546 
15 location world : size =5200000 , type = compartment; 547 
16 location Local in world: size = sizeLocal, type = compartment; 548 
17 location Local in world: size = sizeLocal, type = compartment; 549 
18 location Outside in world : size = sizeOutside, type = compartment; 550 
19 thigh = 4; 551 
20 tlow = 9; 552 
21 month = floor(time/30); 553 
   22 season_time = 1-H( ((month - 12*floor(month/12)) - tlow)*(thigh-(month - 12*floor(month/12))) ); 554 
   23 N = (S1@Local +E@Local + I@Local + R@Local +S2@Local   + MMR1@Local + MMR2@Local); 555 
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Kinetic Laws 556 
24 kineticLawOf BIRTH1:  Mu1 * N; 557 
25 kineticLawOf BIRTH2:  Mu2 * N; 558 
26 kineticLawOf BIRTH3:  Mu3 * N; 559 
27 kineticLawOf  MMR1_S2: MMR1@Local *Tau; 560 
28 kineticLawOf  MMR2_S2: MMR2@Local *Delta; 561 
29 kineticLawOf Death_MMR1 : D_R * MMR1@Local; 562 
30 kineticLawOf Death_MMR2 : D_R * MMR2@Local; 563 
31 kineticLawOf immigration : imrate1/10000; 564 
32 kineticLawOf S1_E: (Beta1 * S1@Local * I@Local)/N * (season_time)  565 
          + (1-season_time)*(Beta * S1@Local * I@Local)/N ; 566 
33 kineticLawOf S2_E: (Beta2 * S2@Local * I@Local)/N * (season_time) 567 
            + (1-season_time)* (Beta * S2@Local * I@Local)/N; 568 
34 kineticLawOf E_I: Alpha * E@Local; 569 
35 kineticLawOf I_R: Gama * I@Local; 570 
36 kineticLawOf Death_S1: D_R * S1@Local; 571 
37 kineticLawOf Death_I: D_R * I@Local ; 572 
38 kineticLawOf Death_E: D_R * E@Local; 573 
39 kineticLawOf Death_S2: D_R * S2@Local; 574 
40 kineticLawOf Death_R: D_R * R@Local; 575 
Species 576 
41 S1 = (BIRTH1,1) >>  S1@Local  + (S1_E,1) << S1@Local + Death_S1 << S1@Local; 577 
42 S2 = (S2_E,1) << S2@Local + Death_S2 << S2@Local + (MMR2_S2,1) >> S2@Local +(MMR1_S2,1) >> 578 
S2@Local; 579 
43 E = (S1_E,1) >> E@Local +(S2_E,1) >> E@Local +(E_I,1) << E@Local+  Death_E << E@Local; 580 
44 I = (E_I,1) >> I@Local +(I_R,1) << I@Local +   Death_I << I@Local + immigration[Outside -> Local](.)I  581 
        + (S1_E,1) (.) I+ (S2_E,1) (.) I; 582 
45 R = (I_R,1) >> R@Local+ Death_R << R@Local ; 583 
46 MMR1 = (BIRTH2,1) >> MMR1@Local  + (MMR1_S2,1) << MMR1@Local+ Death_MMR1 << ; 584 
47 MMR2 = (BIRTH3,1)>> MMR2@Local + (MMR2_S2,1) << MMR2@Local + Death_MMR2 <<  ; 585 
Model component 586 
48 S1@Local[1100000]<*> S2@Local[305500]<*>  E@Local[0]<*> I@Local[20]<*> R@Local[3018600]<*> 587 
MMR1@Local[29250] <*>MMR2@Local[276250] <*> I@Outside[100000] 588 
 589 
 590 
 591 
 592 
 593 
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 595 
 596 
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11 Appendix 2: Sensitivity analysis 603 
1: Incubation period experiments 604 
The analysis per ANOVA is carried out for 14 experiments where the incubation period varied from 605 
12 to 25 days per one step day. The results indicate that at 95% of confidence, no significant 606 
statistical differences between experiments (p = 0.968) and then the null hypothesis (the means of 607 
experiments are equal) cannot be rejected. Hsu’s MCB test and Tukey test imply that varying 608 
incubation period does not affect the number of infected; however, using simulations we can look at 609 
cycles. 100 years of simulations show that by increasing the incubation period the periodicity 610 
changes from 8 to 11 cycles. 611 
Analysis 2: Infectious period experiments 612 
Varying the infectious period from 6 to 9 days per one step day, indicates no significant statistical 613 
differences ( p= 0.114). However, the results validated by the Tukey test are in contrast with the 614 
Hsu’s MCB test results. While the former shows no significant differences, the latter shows 615 
significant differences between an infectious period of 6 days (1
st
 experiment) and the one of 9 days 616 
(4
th
 experiment). In fact, the analysis shows clearly that the mean of the 4
th
 experiment (2739) is 617 
higher than the others (1808, 2113, 2276). In addition the simulation results show that increasing the 618 
infectious period increases the amplitude of the epidemic where the main gap is depicted at the first 619 
peak. 620 
Analysis 3: Transmission rates experiments 621 
Transmission rate experiments are based on changing the basic reproductive number R0 from 4 to 11. 622 
This equates to varying the high transmission rate from 0.44 to 1.83 and the low transmission rate 623 
from 0.19 to 0.81. ANOVA analysis shows that experiments are not statistically significantly 624 
different (p = 0.36). However, simulations over 100 years indicate that increasing the basic 625 
reproductive number leads to a decrease in periodicity. As R0 varies from 4 to 11 the period of cycles 626 
per 100 years of simulation varies from 14 to 6 and the number of cycles varies from 7 to 16 cycles. 627 
During simulations, it was observed that the first epidemic tends to occur sooner with increasing 628 
amplitude as R0 increases.  629 
      Analysis 4: Immunity duration experiments 630 
The analysis per ANOVA of the different values of immunity duration varying from 10 to 80 years, 631 
reveals statistically significant differences. In particular, the analysis depicts four different groups. 632 
The first group includes only one experiment (immunity duration = 10 years).  The second group 633 
includes two experiments (immunity duration = 20 and 30). The third group includes three 634 
experiments (30, 40 and 50). The fourth group includes five experiments (40, 50, 60, 70 and 80), 635 
where the 2
nd
 group overlaps the third group with one experiment (30) and the third group overlaps 636 
the fourth group with two experiments (40, 50). In ANOVA, the experiment which does not share 637 
any group is considered significantly different. This implies that experiment one (10) is significantly 638 
different from all others. This is because small immunity duration tends to increase the pool of 639 
susceptibles faster and the epidemics occur sooner with higher amplitude. Moreover, this analysis 640 
supports the idea that immunity duration has a major effect on the epidemic dynamics, while varying 641 
incubation period, infectious period and transmission rates do not show such large impact on 642 
epidemic curves. 643 
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Analysis 4: Vaccination coverage experiments 644 
Varying vaccination coverage from 75% to 95% in steps of 5 percentage points, indicates at 95% of 645 
confidence no significant statistical differences (p= 0.648) between experiment and H0. The results 646 
validated by Tukey test are similar to those with Hsu’s MCB test results which imply that varying 647 
vaccination coverage does not affect the number of infected; this fact is confirmed by simulations 648 
performed where we can look at cycles. 100 years of simulations show that by increasing the 649 
vaccination coverage the periodicity does not change significantly. From 80% to 95% the simulations 650 
detect 10 cycles where at 75%, the periodicity of cycles is at 9 years. These findings support the 651 
conclusions of DeStefano et al [15] and Donaghy et al [14].   652 
 653 
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12 Appendix 3: Mumps data in England and Wales  674 
Table 1. Model parameters 675 
Parameter Description Value (day) Formula 
B Birth rate 3 10
-5
 Number of birth / Total population 
 Death rate 3.7 10
-5
 Number of death / Total population 
1 No-vaccination rate 2.1 10
-6
 Birth rate -(μ2+μ3) 
μ2  Vaccination rate (MMR1) 2.8 10
-6
 Birth rate * VC1 
μ3 Vaccination rate (MMR2) 2.5 10
-5
 Birth rate * VC2 
 Waning immunity rate (MMR1) 3.4 10
-4
 1/immunity duration of MMR1 
 Waning immunity rate (MMR2) /2 1/immunity duration of MMR2 
 
1 
2 
3 
Transmission rate for : 
- high season and native susceptible 
- high season and modified susceptible 
 - low season 
 
0.7 
0.9 
0.4 
 
 
 = R0 *  
T
3
 Inter-epidemic period [2-5] 
T = 2 *   
 
 
 
 

    [42] 
where A: mean age of infection 
1/ Incubation period [12-25] 1/infection rate 
1/ Infectious period [7-9] 1/recovery rate 
 Immigration rate 0.07 Immigration              
 676 
 677 
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Table 2. Sensitivity analysis summary 678 
Incubation period                             
Values 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
Amplitude 2357 2316 2229 2123 2020 2309 2280 2153 2149 2132 2020 1968 1909 1927 
Period of Cycles 8 9 9 9 9 9 10 10 10 10 11 10 11 11 
Infectious period         
Values  6 7 8 9 
Amplitude  1808 2132 2276 2739 
Period of Cycles  10 10 11 10 
Basic reproductive number             
Values  4 5 6 7 8 9 10 11 
Amplitude  1690 1708 2132 2134 2256 2320 2289 2407 
Period of Cycles  14 12 10 9 9 8 7 6 
Immunity duration               
Values  10 20 30 40 50 60 70 80 
Amplitude  1873 1245 909 668 555 440 371 306 
Period of Cycles  10 8 7 7 6 5 5 4.5 
Vaccination coverage 
   Values  75 80 85 90 95 
Amplitude (100 years peaks) 1694 1660 1552 1536 1413 
Amplitude (10 first peaks) 1602 1587 1547 1504 1410 
Period of Cycles  9 10 10 10 10 
P ovis
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Fig. 1 Confirmed mumps cases, Scotland 1988-2016 and MMR vaccine coverage 679 
Fig. 2 Mumps structure 680 
Fig. 3 Predicted incidence of mumps from 2004 to 2016: : (a) Scenario 1- No vaccination, (b) Scenario 2- 681 
Vaccination without waning immunity, (c) Scenario 3- Vaccination with waning immunity, (d) ) Predicted-682 
Observed data for mumps from 1996 to 2016.. 683 
Fig. 4 Inter-epidemic period against basic reproductive rate R0 for pre-vaccine era 684 
Fig. 5 Infected against vaccination coverage 685 
Fig. 6 The effect of waning immunity: Left axis: Infected-unvaccinated, Infected-unvaccinated/vaccinated. 686 
Right axix: natively susceptible and modified susceptible. 687 
Fig. 7 Infected against duration of immunity 688 
Fig. 8 Inter-epidemic period against basic reproductive rate R0 for post-vaccine era 689 
Fig. 9 Confirmed mumps cases, England and Wales and MMR vaccine coverage 690 
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